Jeffrey L. Ives's most recent trade in Acumen Pharmaceuticals Inc was a trade of 19,500 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Acumen Pharmaceuticals Inc | Jeffrey L. Ives | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 19,500 | 19,500 | - | - | Stock Option (right to buy) | |
| Acumen Pharmaceuticals Inc | Jeffrey L. Ives | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 12,800 | 12,800 | - | 0 | Common Stock | |
| Acumen Pharmaceuticals Inc | Jeffrey L. Ives | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Tvardi Therapeutics Inc. | Jeffrey L. Ives | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 195,000 | 195,000 | - | - | Stock Option (Right to Buy) | |
| Tvardi Therapeutics Inc. | Jeffrey L. Ives | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 150,647 | 198,485 (0%) | 0% | 0 | Common Stock | |
| Acumen Pharmaceuticals Inc | Jeffrey L. Ives | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Tvardi Therapeutics Inc. | Jeffrey L. Ives | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 44,961 | 44,961 | - | - | Stock Option (Right to Buy) | |
| Tvardi Therapeutics Inc. | Jeffrey L. Ives | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 32,362 | 47,838 (0%) | 0% | 0 | Common Stock | |
| Tvardi Therapeutics Inc. | Jeffrey L. Ives | Director | Sale of securities on an exchange or to another person at price $ 9.05 per share. | 15 Jul 2022 | 3,600 | 15,476 (0%) | 0% | 9.1 | 32,580 | Common Stock |
| Acumen Pharmaceuticals Inc | Jeffrey L. Ives | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Tvardi Therapeutics Inc. | Jeffrey L. Ives | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 16,996 | 16,996 | - | - | Stock Option (Right to Buy) | |
| Tvardi Therapeutics Inc. | Jeffrey L. Ives | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 11,876 | 19,076 (0%) | 0% | 0 | Common Stock | |
| Tvardi Therapeutics Inc. | Jeffrey L. Ives | Director | Sale of securities on an exchange or to another person at price $ 16.04 per share. | 12 Nov 2021 | 8,180 | 7,200 (0%) | 0% | 16.0 | 131,207 | Common Stock |
| Acumen Pharmaceuticals Inc | Jeffrey L. Ives | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Tvardi Therapeutics Inc. | Jeffrey L. Ives | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 10,800 | 10,800 | - | - | Stock Option (Right to Buy) | |
| Tvardi Therapeutics Inc. | Jeffrey L. Ives | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 7,200 | 17,900 (0%) | 0% | 0 | Common Stock | |
| Tvardi Therapeutics Inc. | Jeffrey L. Ives | Director | Sale of securities on an exchange or to another person at price $ 13.05 per share. | 03 Jun 2021 | 2,520 | 15,380 (0%) | 0% | 13.1 | 32,886 | Common Stock |
| Tvardi Therapeutics Inc. | Jeffrey L. Ives | Director | Sale of securities on an exchange or to another person at price $ 15.75 per share. | 19 Nov 2020 | 2,500 | 10,700 (0%) | 0% | 15.7 | 39,373 | Common Stock |